Annals of Internal Medicine: Clinical Cases (Jan 2024)

Post–COVID-19 Vaccine Myopericarditis in a Transgender Man Undergoing Gender-Affirming Testosterone Therapy

  • Jonathan Zhou,
  • Elizabeth Dimmock,
  • Evan Cottrill,
  • Henry Ng

DOI
https://doi.org/10.7326/aimcc.2023.0544
Journal volume & issue
Vol. 3, no. 1

Abstract

Read online

Myopericarditis is a rare complication seen after mRNA COVID-19 vaccination. This complication has been seen most frequently in young adult men, ages 16 years and older, within 1 week of receiving a second dose of the mRNA COVID-19 vaccine (Pfizer–BioNtech and Moderna). In this case report, we describe a transgender man who was receiving testosterone-based gender affirmation therapy and developed myopericarditis after receiving his second mRNA COVID-19 vaccination. This case highlights that sex-based health risks may be related to specific sex-traits.